FILE - A supermoon rises through clouds over the skyline of lower Manhattan, Aug. 1, 2023, as seen from West Orange, N.J. Stargazers are in for a double treat on Wednesday night, Aug. 30: a rare blue supermoon with Saturn peeking from behind. The cosmic curtain rises Wednesday night with the second full moon of August, the reason it’s considered blue. It’s dubbed a supermoon because it’s closer to Earth than usual, appearing especially big and bright. (AP Photo/Seth Wenig, File)
By Marcia Dunn
Stargazers are in for a double treat on Aug. 30: a rare blue supermoon with Saturn peeking from behind.
The cosmic curtain rises Wednesday night with the second full moon of the month, the reason it’s considered blue. It’s dubbed a supermoon because it’s closer to Earth than usual, appearing especially big and bright.
This will be the closest full moon of the year, just 222,043 miles (357,344 kilometers) or so away. That’s more than 100 miles (160 kilometers) closer than the Aug. 1 supermoon.
As a bonus, Saturn will be visible as a bright point 5 degrees to the upper right of the moon at sunset in the east-southeastern sky, according to NASA. The ringed planet will appear to circle clockwise around the moon as the night wears on.
If you missed the month’s first spectacle, better catch this one. There won’t be another blue supermoon until 2037, according to Italian astronomer Gianluca Masi, founder of the Virtual Telescope Project.
Clouds spoiled Masi's attempt to livestream the supermoon rising earlier this month. He’s hoping for clearer skies this time so he can capture the blue supermoon shining above St. Peter’s Basilica at the Vatican.
Weather permitting, observers don’t need binoculars or telescopes — “just their own eyes." said Masi.
“I’m always excited to admire the beauty of the night sky,” he said, especially when it features a blue supermoon.
The first supermoon of 2023 was in July. The fourth and last will be in September.
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home.
Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
Direct health care company Nomi Health recently raised $110 million in a Series A round. Nomi Health lets public and private organizations directly purchase healthcare at reduced costs, and pay providers in real-time. It also delivers healthcare directly to under-served communities via its fleet of mobile care units, which the company says is the largest in the country. Nomi Health says its mission is to improve the health care experience for all Americans. Nomi Health CEO Mark Newman joined Cheddar News' Closing Bell to discuss.
The airline industry says it is contending with staff shortages that threaten to hamper operations amid the COVID resurgence, andDelta Airlines CEO Ed Bastian called on the CDC to revise its guidance for vaccinated workers who test positive from a 10-day quarantine to just five. Chuck Liberman, chief investment officer and managing partner at Advisors Capital Management LLC, joined Cheddar to talk about the current guidance on isolation and why he believes the omicron variant calls for more relaxed guidance given its reportedly mild symptoms.
The boys discuss President Biden's plans to send out free rapid tests as the testing supply chain starts to buckle ahead of the holidays. Also, why aren't Americans having more babies, and The Matrix returns.
NASA is launching its new generation of space telescopes just before Christmas. The James Webb Space Telescope, set to launch on December 24th, will succeed the Hubble space telescope as the world's most powerful complex space observatory. The project has been 30 years in the making and is one of the most highly anticipated space science missions of the 21st century. Klaus Pontoppidan, astronomer and JWST Project Scientist at the Space Telescope Science Institute joined Cheddar's Opening Bell to discuss.
With Omicron becoming the dominant COVID-19 variant in the U.S., President Joe Biden announced that he will make 500 million rapid tests available to Americans in January 2022. Cheddar News speaks with Dr. Shereef Elnahal, President and CEO of University Hospital why testing is key to combatting the spread of the virus.
